Neuralink reposted Musk’s Monday post on X, but did not publish any additional statements acknowledging the human implant. The company did not immediately respond to AP’s requests for comment on Tuesday.
Neuralink previously announced that the US Food and Drug Administration had approved its “investigational device exemption”, which generally allows a sponsor to begin a clinical study “in patients who fit the inclusion criteria,” the FDA said Tuesday. The agency pointed out that it can’t confirm or disclose information about a particular study of this kind.
Neuralink’s device is about the size of a large coin and is designed to be implanted in the skull, with ultra-thin wires going directly into the brain. In its September announcement, Neuralink said the wires would be surgically placed in a region of the brain that controls movement intention. The initial goal of the so-called brain computer interface is to give people the ability to control a computer cursor or keyboard using their thoughts alone.
In a separate Monday post on X, Musk said that the first Neuralink product is called “Telepathy” — which, he said, will enable users to control their phones or computers “just by thinking”. He added that initial users would be those who have lost use of their limbs.
It’s unclear how well this device or similar interfaces will ultimately work, or how safe they might be. Clinical trials are designed to collect data on safety and effectiveness.
In response to Musk’s Monday announcement, King’s College London professor Anne Vanhoestenberghe noted Neuralink has now joined a “rather small group” of companies that have implanted their devices in humans. But measuring success and safety will take time — and disclosure of more information from Neuralink.
“We know Elon Musk is very adept at generating publicity for his company, so we may expect announcements as soon as they begin testing, although true success in my mind should be evaluated in the long term, by how stable the interface is over time, and how much it benefits the participant,” stated Vanhoestenberghe, who specialises in active implantable medical devices. She added there is “insufficient information” to gauge the procedure’s safety at this time.
